Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Outlook Therapeutics, Inc. OTLK

Set alert

Price alert · OTLK

All alert types
0.48 USD +0.01 +1.56%

As of Nov 3, 9:59 AM ET

Bid
0.47 × 2
Ask
0.48 × 2
0.4625 Day range 0.4795
0.198 52-week range 2.47
YTD
-69.84%
1 year
-63.35%
Open
0.4625
Prev close
0.4692
Mkt cap
116.00M
Vol
362.00K
Avg vol
10.14M
EPS
-0.70
P/E
0.00
Div yield
0.00%
More statistics
Low
0.4625
High
0.4795
Forward P/E
-0.55
Beta
0.63
Short ratio
1.26
Inst. own
35.63%
Dividend
0.00
Ex-div date
Earnings
Dec 27, 2024
50-d avg
4.24
200-d avg
6.73
1y target
24.80

MAX chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Dec 2, 2024Downgrade: Chardan Capital · Buy → Neutral
Signals (24)
NameDateAgo
SMA: BearishAug 1, 20263 months ago
SMA: BullishJun 1, 20265 months ago
SMA: BearishJan 1, 202610 months ago
SMA: BullishNov 1, 20251 year ago
MACD: Buy SignalMar 1, 20242 years ago
MACD: Sell SignalOct 1, 20233 years ago
SMA: BearishAug 1, 20233 years ago
SMA: BearishAug 1, 20233 years ago
SMA: BullishJun 1, 20233 years ago
SMA: BullishMay 1, 20233 years ago
SMA: BearishMay 1, 20224 years ago
SMA: BullishFeb 1, 20224 years ago
SMA: BearishNov 1, 20215 years ago
SMA: BearishOct 1, 20215 years ago
SMA: BullishApr 1, 20215 years ago
SMA: BullishFeb 1, 20215 years ago
SMA: BearishJan 1, 20215 years ago
SMA: BullishNov 1, 20206 years ago
SMA: BearishAug 1, 20206 years ago
SMA: BullishMay 1, 20206 years ago

Newest 20 of 24.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 24.80 +5104.6% upside
Target (low)
9.00
Target (mean)
24.80
Target (high)
38.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
  • Strong buy1
  • Buy4
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 6
  • 1 month ago 6
  • 2 months ago 7
  • 3 months ago 7

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

OTLK analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.90-0.91 – -0.89-0.936+3.9%00.0%2
Next quarter-0.96-0.99 – -0.93-0.778-23.4%00.0%2
Current year-4.01-4.04 – -3.98-4.37+8.3%00.0%2
Next year-2.63-3.01 – -2.24-4.01+34.5%7.63M0.0%2

Upgrades and downgrades

The latest rating changes

OTLK analyst upgrades and downgrades
DateFirmActionFromTo
Dec 2, 2024Chardan CapitalDowngradeBuyNeutral
Nov 29, 2024BTIGMaintainedBuyBuy
Nov 29, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 16, 2024Chardan CapitalMaintainedBuyBuy
Aug 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
May 17, 2024HC Wainwright & Co.ReiteratedBuyBuy
Mar 27, 2024BTIGUpgradeNeutralBuy
Mar 25, 2024HC Wainwright & Co.MaintainedBuyBuy
Feb 15, 2024Chardan CapitalUpgradeNeutralBuy
Jan 25, 2024GuggenheimUpgradeNeutralBuy
Jan 25, 2024Brookline CapitalUpgradeHoldBuy
Dec 29, 2023Ascendiant CapitalMaintainedBuyBuy
Dec 27, 2023Capital OneUpgradeEqual-WeightOverweight
Nov 3, 2023HC Wainwright & Co.MaintainedBuyBuy
Aug 31, 2023Chardan CapitalDowngradeBuyNeutral
Aug 31, 2023HC Wainwright & Co.DowngradeBuyNeutral
Aug 30, 2023Brookline CapitalDowngradeBuyHold
Aug 30, 2023Cantor FitzgeraldDowngradeOverweightNeutral
Aug 30, 2023BTIGDowngradeBuyNeutral
Aug 15, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 15, 2023Chardan CapitalReiteratedBuyBuy
Jul 26, 2023HC Wainwright & Co.ReiteratedBuyBuy
Jul 13, 2023Capital OneInitiated—Overweight
May 16, 2023Chardan CapitalReiteratedBuyBuy
May 16, 2023HC Wainwright & Co.ReiteratedBuyBuy
Apr 3, 2023GuggenheimInitiated—Buy
Feb 15, 2023HC Wainwright & Co.Maintained—Buy
Feb 6, 2023Cantor FitzgeraldInitiated—Overweight
Jan 6, 2023HC Wainwright & Co.Maintained—Buy
Oct 31, 2022BTIGInitiated—Buy